Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Incyte Corporation INCY

Healthcare Biotechnology
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI... see more

Current News (NDAQ:INCY)

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma

Business Wire January 5, 2026

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma

Business Wire December 22, 2025

Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer

Business Wire December 22, 2025

Incyte to Present at Upcoming Investor Conference

Business Wire December 18, 2025

Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma

Business Wire December 17, 2025

Incyte Announces Change to its Board of Directors

Business Wire December 12, 2025

Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia

Business Wire December 8, 2025

Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025

Business Wire December 7, 2025

Incyte's First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA

Business Wire December 7, 2025
View More News ››

Opinion & Analysis (NDAQ:INCY)

Immuno-Oncology candidate yields 'impressive' early clinical results

Streetwise Reports December 7, 2017

3 Biotech ETFs Rally On Merger News

Benzinga.com  December 8, 2014

Stock picks that include a couple of Canadian miners

J.W. Cotton June 26, 2009
View More Opinion ››

Bullboard Posts (NDAQ:INCY)

Sell buddy sell.Wow.

Otherwise you guys out there will be losing your shorts and it's time to be getting out of it
coolfooldumbguy - March 17, 2025

INCY / INCYTE corporation - A good Investment option

<< View Post To Watch Video >>
flyjeetu - May 26, 2021

Take a look at Theralase vtlt

They may hold the cure for bladder cancer as well as brain and lung cancer In clinical trial for bladder cancer looking very good .This...
goregil - February 12, 2019

Buy rating and $19 price

Piper Jaffray adds Incyte Corp. to its Alpha List, citing a positive data release on Incyte's lead JAK2 inhibitor at the European...
mart33 - April 8, 2008

news/ratings ta

NEW YORK, February 18 - Analysts at UBS maintain their "buy" rating on Incyte Corp  while reducing their estimates for the...
mart33 - March 24, 2008

Incyte Reports 47% UP ( INCY : Nasdaq)

10/17/00 - Incyte Reports 47% Year-to-year Increase in Third Quarter Revenue PALO ALTO, Calif., Oct. 17 /PRNewswire/ -- Incyte...
Nano2000 - October 18, 2000
View more Bullboard ››

Sparta Capital Ltd.

Sparta Capital Ltd.

Sparta Capital Ltd. engages in environment, health, and transportation businesses in Canada. It operates through Electronics ...
View More »

Podcasts